Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NEO - Neogenomics Inc.


IEX Last Trade
16.52
0.100   0.605%

Share volume: 517,281
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$16.42
0.10
0.61%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
-0.84%
1 Month
-4.34%
3 Months
18.00%
6 Months
6.17%
1 Year
11.85%
2 Year
67.38%
Key data
Stock price
$16.52
P/E Ratio 
-26.95
DAY RANGE
$16.12 - N/A
EPS 
-$0.62
52 WEEK RANGE
$11.03 - $21.22
52 WEEK CHANGE
$0.09
MARKET CAP 
2.117 B
YIELD 
N/A
SHARES OUTSTANDING 
128.158 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.62
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$459,332
AVERAGE 30 VOLUME 
$557,339
Company detail
CEO:
Region: US
Website: https://neogenomics.com/
Employees: 1,345
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig

Recent news